







ANALYSIS OF EFFECTIVENESS AND SAFETY OF TRALOKINUMAB IN MODERATE-SEVERE ATOPIC DERMATITIS

Urbano-Fernández MA¹, Salmerón-Cobos AY², Cano-Domínguez S², Rodríguez-Goicoechea M³, Sierra-Torres MI², Cantudo-Cuenca R², Jiménez-Morales A²

1 Hospital Universitario San Cecilio, Granada. 2 Hospital Virgen de las Nieves, Granada. 3 Complejo Hospitalario de Jaén, Jaén (Spain).

OBJETIVES

The aim of the study is to evaluate the effectiveness and safety of tralokinumab in patients with moderate-severe AD in three tertiary hospitals.

MATERIALS AND METHODS

Observational Retrospective

Multicenter

Inclusion criteria
Patients in treatment April 2022 –
September 2023.

✓ At least in week 16.

Demograpic variables

Age

Sex

variables

Clinical

Pharmacological variables

Eczema Area and Severity Index 50 y 75 (EASI)

> Investigator Global Assessment (IGA)

Body Surface Area (BSA)

Dosage

Treatment duration

Previous and concomitant treatments

Adverse effects

Information resources

Digitalized medical record (Diraya®) and the electronic prescription program (Athos Prisma®).


RESULTADOS



- n= 39 patients
- **9** 56% (18/32)
- 37,6(16-66) years

Concomitant treatments

- Topical corticosteroids: 65%
- Cyclosporine: 12,5%
- MTX: 6%



Effectiveness	Week 16	Week 20
EASI-50	33%	28%
EASI-75	23%	23%
BSA 0	18%	
BSA reduction	44%	
IGA 0-1	15%	

Adverse effects: 10%



- Syncope
- Respiratory infection
- Headache
- Conjunctivitis and xerosis

CONCLUSIONS

Tralokinumab is an innovative alternative in patients with moderate-severe AD refractory to other therapies. More data on long-term efficacy and safety are needed.

